AbbVie makes psychedelic play with $2bn Gilgamesh collaboration
AbbVie is making a push into the psychedelic frontier as it joins forces with US-based Gilgamesh Pharmaceuticals to target therapies …
Cytokinetics looks to take on BMS’ Camzyos in hypertrophic cardiomyopathy
Cytokinetics has announced positive Phase III trial results with its lead drug aficamten being explored as a treatment for a …
AI database to bolster research for GLP1-RAs as precision medicines
An AI database that utilises real-world data (RWD) could help sponsors decide where to next investigate glucagon-like peptide-1 receptor agonists …
Sanofi to make €1bn biomanufacturing investment in France
Sanofi has announced an investment exceeding €1bn ($1.07bn) to expand biomanufacturing capacities at its sites in France. The company will enhance …
UK Government expands opioid overdose treatment access
The UK Government is set to revise legislation to allow a wider range of professionals, including paramedics, nurses, police officers, …
Pint Pharma announces Orladeyo approval in Mexico for HAE prevention
Pint Pharma has announced that Mexico's Federal Commission for Protection against Health Risks (COFEPRIS) has granted approval for Orladeyo (berotralstat) …
NHS introduces Pfizer’s tafamidis for ATTR-CM treatment
The UK's National Health Service (NHS) has introduced Pfizer's tafamidis for transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare heart condition characterised …
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
Zai Lab has announced that its New Drug Application (NDA) for Augtyro (repotrectinib) has been greenlit by China’s National Medical …
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
Japanese pharma company Takeda has signed an exclusive, worldwide option and licence agreement for AC Immune’s amyloid beta-targeting Alzheimer’s disease …
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
Regeneron and Sanofi could soon be adding another indication to its blockbuster immunology drug Dupixent (dupilumab) after the US Food …
Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
Fulcrum Therapeutics has signed a $1bn exclusive licence deal with Sanofi to develop and commercialise the investigational facioscapulohumeral muscular dystrophy …
Dementia Action Week 2024: the future of Alzheimer’s diagnostics
Dementia Action Week 2024, which starts today, shines a spotlight on Alzheimer’s disease, the most common cause of dementia. The approval …
Lula’s progress plan for Brazil: A year on
On 30 May 2023, President Lula da Silva assembled the first South American summit in nearly a decade. In reviving …
Sanofi signs $1.2bn licensing agreement for Novavax’s Covid-19 vaccine
Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine. Starting in 2025, the drugmaker …
RAPT terminates Phase II trials for lead candidate following clinical hold
RAPT Therapeutics has announced plans to terminate two Phase II trials for its lead candidate, zelnecirnon (RPT193), three months after …